Opus Genetics Shares Surge Ahead of Key Retinal Disease Trial Data

Opus Genetics Inc. saw its stock rally 5.9% in pre-market trading Tuesday as investors positioned themselves for a highly anticipated clinical data release. The surge comes ahead of the scheduled readout of three-month topline data from a key trial for its gene therapy candidate targeting inherited retinal diseases.

A Pivotal Data Readout

The focus of the market is on Cohort 1 of the OPGx-BEST1 Phase 1/2 trial. This study is evaluating a gene replacement therapy for patients with two debilitating conditions: Best Vitelliform Macular Dystrophy and Autosomal-Recessive Bestrophinopathy.

According to a confirmed schedule, the data is set to be released on September 1, 2026. Analysts have long identified this event as a defining moment for the company, with positive results potentially de-risking the entire program and validating its therapeutic approach.

Analyst Support and Pipeline Progress

Investor optimism is bolstered by strong conviction from Wall Street analysts. Several firms have reiterated positive outlooks in anticipation of the data, viewing it as a major value-creation event for Opus Genetics.

Ad

• BTIG: Maintains a Buy rating with a $12 price target.
• B.Riley: Holds a Buy rating with a $10 price target.
• Cantor Fitzgerald: Has also reiterated its Buy stance.

Confidence in the company's operational capabilities is further supported by recent progress in its broader pipeline. In early August, Opus completed enrollment in its registrational Phase 3 trial of OPGx-LCA5, another one of its gene therapy candidates.

Defying Broader Market Weakness

The rally in Opus Genetics is particularly notable as it comes against a negative macroeconomic backdrop. Major U.S. indices, including the S&P 500 and Nasdaq, were trading lower in the pre-market session amid escalating geopolitical tensions and concerns over potential Federal Reserve rate hikes.

The ability of the stock to trade sharply higher highlights the company-specific nature of the catalyst. The market is treating the upcoming clinical data as a binary event significant enough to outweigh broader headwinds for growth and biotech equities.